vs

Side-by-side financial comparison of IMMUCELL CORP (ICCC) and MYRIAD GENETICS INC (MYGN). Click either name above to swap in a different company.

MYRIAD GENETICS INC is the larger business by last-quarter revenue ($209.8M vs $5.5M, roughly 38.1× IMMUCELL CORP). On growth, MYRIAD GENETICS INC posted the faster year-over-year revenue change (-0.4% vs -8.4%). Over the past eight quarters, IMMUCELL CORP's revenue compounded faster (3.9% CAGR vs 1.9%).

ImmuCell Corp is a US-based animal health biotechnology company that develops, manufactures and markets innovative products for livestock, primarily dairy cattle. Its core offerings include preventive and therapeutic solutions for common bovine health issues such as mastitis, serving agricultural producers and veterinary providers across North America.

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a pati...

ICCC vs MYGN — Head-to-Head

Bigger by revenue
MYGN
MYGN
38.1× larger
MYGN
$209.8M
$5.5M
ICCC
Growing faster (revenue YoY)
MYGN
MYGN
+8.0% gap
MYGN
-0.4%
-8.4%
ICCC
Faster 2-yr revenue CAGR
ICCC
ICCC
Annualised
ICCC
3.9%
1.9%
MYGN

Income Statement — Q3 2025 vs Q4 2025

Metric
ICCC
ICCC
MYGN
MYGN
Revenue
$5.5M
$209.8M
Net Profit
$-139.7K
Gross Margin
42.9%
70.0%
Operating Margin
0.4%
-2.7%
Net Margin
-2.5%
Revenue YoY
-8.4%
-0.4%
Net Profit YoY
80.1%
EPS (diluted)
$-0.02
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ICCC
ICCC
MYGN
MYGN
Q4 25
$209.8M
Q3 25
$5.5M
$205.7M
Q2 25
$6.4M
$213.1M
Q1 25
$8.1M
$195.9M
Q4 24
$7.8M
$210.6M
Q3 24
$6.0M
$213.3M
Q2 24
$5.5M
$211.5M
Q1 24
$7.3M
$202.2M
Net Profit
ICCC
ICCC
MYGN
MYGN
Q4 25
Q3 25
$-139.7K
$-27.4M
Q2 25
$501.9K
$-330.5M
Q1 25
$1.4M
$-100.0K
Q4 24
Q3 24
$-701.7K
$-22.1M
Q2 24
$-1.5M
$-36.7M
Q1 24
$-437.9K
$-26.0M
Gross Margin
ICCC
ICCC
MYGN
MYGN
Q4 25
70.0%
Q3 25
42.9%
69.9%
Q2 25
43.7%
71.2%
Q1 25
41.6%
68.5%
Q4 24
36.5%
71.7%
Q3 24
26.3%
70.2%
Q2 24
22.5%
69.6%
Q1 24
31.6%
68.1%
Operating Margin
ICCC
ICCC
MYGN
MYGN
Q4 25
-2.7%
Q3 25
0.4%
-11.3%
Q2 25
8.8%
-154.5%
Q1 25
13.9%
-14.8%
Q4 24
8.0%
-18.6%
Q3 24
-9.6%
-9.4%
Q2 24
-25.3%
-17.3%
Q1 24
-4.1%
-13.8%
Net Margin
ICCC
ICCC
MYGN
MYGN
Q4 25
Q3 25
-2.5%
-13.3%
Q2 25
7.8%
-155.1%
Q1 25
17.9%
-0.1%
Q4 24
Q3 24
-11.7%
-10.4%
Q2 24
-28.0%
-17.4%
Q1 24
-6.0%
-12.9%
EPS (diluted)
ICCC
ICCC
MYGN
MYGN
Q4 25
$-0.09
Q3 25
$-0.02
$-0.29
Q2 25
$0.06
$-3.57
Q1 25
$0.16
$0.00
Q4 24
$0.09
$-0.47
Q3 24
$-0.09
$-0.24
Q2 24
$-0.20
$-0.41
Q1 24
$-0.06
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ICCC
ICCC
MYGN
MYGN
Cash + ST InvestmentsLiquidity on hand
$3.9M
$149.6M
Total DebtLower is stronger
$9.5M
$119.9M
Stockholders' EquityBook value
$29.8M
$368.0M
Total Assets
$45.7M
$706.6M
Debt / EquityLower = less leverage
0.32×
0.33×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ICCC
ICCC
MYGN
MYGN
Q4 25
$149.6M
Q3 25
$3.9M
$145.4M
Q2 25
$74.4M
Q1 25
$91.8M
Q4 24
$3.8M
$102.4M
Q3 24
$99.9M
Q2 24
$1.3M
$97.3M
Q1 24
$960.3K
$104.3M
Total Debt
ICCC
ICCC
MYGN
MYGN
Q4 25
$119.9M
Q3 25
$9.5M
$119.5M
Q2 25
Q1 25
$8.7M
Q4 24
$9.0M
Q3 24
$9.4M
Q2 24
$9.8M
Q1 24
$10.2M
Stockholders' Equity
ICCC
ICCC
MYGN
MYGN
Q4 25
$368.0M
Q3 25
$29.8M
$372.8M
Q2 25
$29.9M
$388.1M
Q1 25
$29.0M
$704.9M
Q4 24
$27.5M
$701.1M
Q3 24
$26.4M
$731.7M
Q2 24
$23.5M
$740.5M
Q1 24
$24.6M
$760.0M
Total Assets
ICCC
ICCC
MYGN
MYGN
Q4 25
$706.6M
Q3 25
$45.7M
$728.1M
Q2 25
$46.7M
$677.3M
Q1 25
$45.6M
$1.0B
Q4 24
$45.1M
$1.0B
Q3 24
$44.4M
$1.1B
Q2 24
$41.9M
$1.1B
Q1 24
$43.1M
$1.1B
Debt / Equity
ICCC
ICCC
MYGN
MYGN
Q4 25
0.33×
Q3 25
0.32×
0.32×
Q2 25
Q1 25
0.30×
Q4 24
0.33×
Q3 24
0.36×
Q2 24
0.42×
Q1 24
0.41×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ICCC
ICCC
MYGN
MYGN
Operating Cash FlowLast quarter
$-1.2M
$10.6M
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-32.3%
Capex IntensityCapex / Revenue
10.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$715.4K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ICCC
ICCC
MYGN
MYGN
Q4 25
$10.6M
Q3 25
$-1.2M
$21.1M
Q2 25
$1.6M
$-13.6M
Q1 25
$1.6M
$-16.3M
Q4 24
$-3.1K
$6.6M
Q3 24
$-639.3K
$700.0K
Q2 24
$581.8K
$2.6M
Q1 24
$418.5K
$-18.6M
Free Cash Flow
ICCC
ICCC
MYGN
MYGN
Q4 25
Q3 25
$-1.8M
Q2 25
$1.4M
Q1 25
$1.2M
Q4 24
$-199.3K
Q3 24
$-727.7K
Q2 24
$471.0K
Q1 24
$348.1K
FCF Margin
ICCC
ICCC
MYGN
MYGN
Q4 25
Q3 25
-32.3%
Q2 25
22.4%
Q1 25
15.4%
Q4 24
-2.6%
Q3 24
-12.1%
Q2 24
8.6%
Q1 24
4.8%
Capex Intensity
ICCC
ICCC
MYGN
MYGN
Q4 25
Q3 25
10.8%
Q2 25
2.4%
Q1 25
4.1%
Q4 24
2.5%
Q3 24
1.5%
Q2 24
2.0%
Q1 24
1.0%
Cash Conversion
ICCC
ICCC
MYGN
MYGN
Q4 25
Q3 25
Q2 25
3.19×
Q1 25
1.09×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons